

Lodi, 24 Oct 2025

## EU DECLARATION OF CONFORMITY

The undersigned company **IBSA Farmaceutici Italia srl**, located at Via Martiri di Cefalonia, 2 – 26900 LODI (ITALY), registered on EUDAMED with the following registration number:

SRN: IT-MF-000008111

Manufacturer of the following medical device:

Product name: HILOW VISCO-SUPPLETIVE JOINT DEVICE

Trade name and presentation: SINOVIAL HL – 3,2% - 32 mg(H-HA) + 32 mg (L-HA)/2 ml Hyaluronic Acid Sodium Salt

Batch nr: E05357

Quantity: 1.078

Manufacturing Date: 2025/05

Expiry Date: 2028/05

Certificate of analysis nr: 170000060420

Basic UDI-DI: 803363895IA0014R

Risk class: The medical device has been classified as Class III, according to the rules 8 of the Annex VIII of the Regulation EU 2017/745

Sterile: YES

Device with a measuring function: NO

Device intended for clinical investigations: NO

Common Specifications used:

Name and Identification number of Notified Body: Eurofins Product Testing Italy S.r.l. ON0477

Conformity assessment procedure performed: pursuant to Article 52 point 3 that follows the dictates of Annex IX "CONFORMITY ASSESSMENT BASED ON A QUALITY MANAGEMENT SYSTEM AND ON ASSESSMENT OF TECHNICAL DOCUMENTATION"

EC certificate N°: EU QUALITY MANAGEMENT SYSTEM CERTIFICATE N° EPT 0477.MDR.22/4842  
EU TECHNICAL DOCUMENTATION ASSESSMENT CERTIFICATE N° EPT 0477.MDR.22/4841


### DECLARES

That the above information is authentic, accurate and the above-mentioned Medical Device fulfils all the provisions laid down and is in conformity with the REGULATION (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017.

This EU declaration of conformity is hereby issued under the sole responsibility of the manufacturer of medical device. The Manufacturer set up a systematic procedure for evaluating the acquired experience in the use of medical devices in the phase following the production and for foreseeing an adequate system to be applied for corrective actions when needed, in case of incidents according to the provisions laid down in accordance with the Chapter VII, of the above-mentioned REGULATION, as amended.

The Manufacturer commits to filing and to making available to the competent Authorities the technical documentation described in the Annex II of REGULATION (EU) 2017/745, for a period of at least fifteen years from the date of production of the last batch.

IBSA Farmaceutici Italia S.r.l



[Cinzia Pagliari, PRRC]

Sede legale e Stabilimento  
Via Martiri di Cefalonia, 2 - 26900 LODI  
Tel. +39 0371 6171 - Fax +39 0371 617244

Stabilimento di Cassina de' Pecchi  
S.S. 11, Padana Superiore km 160 - 20051 Cassina de' Pecchi (MI)  
Tel. +39 0371 617292 Fax +39 0371 617368

Sede di Roma  
Via del Tritone, 169 - 00187 ROMA  
Tel. +39 06 94378600 Fax +39 06 94378699

Sede amministrativa  
Via della Filanda, 30 - 26900 LODI  
Tel. +39 0371 617292 Fax +39 0371 617368



Lodi, 24 Oct 2025

## CERTIFICATE OF CONFORMITY

The undersigned company IBSA Farmaceutici Italia srl, located at Via Martiri di Cefalonia, 2 – 26900 LODI (ITALY), registered on EUDAMED with the following registration number:

SRN: IT-MF-000008111

in conformity with Regulation (EU) 2017/745 Art. 22.1 a), as amended, combines the following Medical Devices in order to place them on the market as a System:

- SINOVIAL HL 3,2% bears CE Mark 0477 and is manufactured by IBSA Farmaceutici Italia srl
- Needle 21 G x 1 ½" bear CE Mark 0197 and are manufactured by TERUMO Europe N.V

IBSA combines the listed Devices in compliance with their Intended Purpose and within the Limits of Use specified by the Manufacturer.

These SYSTEM has the following specifications:

Product description: SINOVIAL HL– 3.2% - 32 mg(H-HA) + 32 mg (L-HA)/2 ml Hyaluronic Acid Sodium Salt with needle 21 G x 1 ½"

Basic UDI-DI: 803363895IAK00167

Batch nr. E05357

Certificate of Analysis nr. 170000060420

Quantity: 1.078

Manufacturing Date: 2025/05

Expiry date: 2028/05

Furthermore, in conformity with Regulation (EU) 2017/745 Art. 22.2, IBSA Farmaceutici Italia

### DECLARES THAT

- it's been verified the mutual compatibility of the devices.
- it's been packaged the system and supplied relevant information to users.
- the activity of combining devices was subject to appropriate methods of internal monitoring, verification, and validation.

IBSA Farmaceutici Italia S.r.l

  
 \_\_\_\_\_  
 [Cinzia Pagliari, PRRC]



**Sede legale e Stabilimento**  
Via Martiri di Cefalonia, 2 - 26900 LODI  
Tel. +39 0371 6171 - Fax +39 0371 617244

**Stabilimento di Cassina de' Pecchi**  
S.S. 11, Padana Superiore km 160 - 20051 Cassina de' Pecchi (MI)  
Tel. +39 0371 617292 Fax +39 0371 617368

**Sede di Roma**  
Via del Tritone, 169 - 00187 ROMA  
Tel. +39 06 94378600 Fax +39 06 94378699

**Sede amministrativa**  
Via della Filanda, 30 - 26900 LODI  
Tel. +39 0371 617292 Fax +39 0371 617368